Enhancing Survival Through Innovative Immune Modulation

We have a strong oncology pipeline with multiple near-term value inflection milestones.

Stock information

IPO date: November 8, 2021
Denomination: MaaT Pharma
ISIN code/ticker: FR0012634822 / MAAT
ICB classification: 20103010 – Biotechnology
Listing market: Euronext Paris regulated market
Eligible for the PEA and PEA-PME schemes and for the 150-0 B ter scheme of the CGI
Analysts covering the share:
- Gilbert Dupont Groupe Société Générale : Pierre-Alexandre Desir & Guillaume Cuvillier
- KBC Securities: Thomas Vranken & Jacob Mekhael
- Kempen: Suzanne van Voorthuizen & Luísa Morgado
- Kepler Cheuvreux: Christophe Dombu
- Portzamparc Groupe BNP Paribas: Mohamed Kaabouni
- Stifel: Clémence Thiers & Eric Le Berrigaud

Download our corporate presentation

Board of Directors

Karim Dabbagh

Chairman of the Board – Independent director

Karim Dabbagh, PhD, was appointed Chairman and independent Director of MaaT Pharma in June 2023, succeeding Jean-Marie Lefevre who will continue to serve as a Board member.
Based in the U.S., Karim Dabbagh, president and CEO of Second Genome Inc., renowned for his innovative work in microbiome science and former executive at Pfizer and Roche, brings extensive experience in pharmaceutical development.

PhD in Biochemistry from University College, London
BSc (Hons) in Biotechnology from Imperial College, London

Jean-Marie Lefevre

Non-Executive Director

Jean-Marie Lefèvre is a member of the Audit Committee and a non executive director at MaaT Pharma.
Jean-Marie Lefèvre has held senior manage-ment positions in large companies such as LVMH and Bongrain before joining Biocodex where he was Chairman and CEO until the end of 2020 and of which he is currently Chairman. During his ten-ure as CEO at Biocodex, he initiated the creation of numerous subsidiaries, and greatly diversified the product portfolio of the Biocodex Group. At the same time, he wanted his Group to invest in and support the development of healthcare start-ups, including MaaT Pharma.

Engineering degree Ecole Centrale Paris, MBA from Insead

Dorothée Burkel

Independent Director

Dorothée Burkel holds a Master's degree from the Institut d'Etudes Politiques in Paris and is an independent director on the board of Directors. She is also Director of Human Resources, Information Systems and Communication and a member of the Executive Committee of PartnerRe. She brings decades of high-level experience in human resources and communication, having participated in the transformation of companies at an international level in the new technology and financial sectors.
She was formerly HR Director EMEA at Google and HR Director France at AOL.

Chief Corporate and People Operations Officer

Hervé Affagard

CEO, Founder

Hervé Affagard is the CEO and founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. He founded MaaT Pharma in late 2014 together with onco-hematologist Prof. Mohammad Mohty and microbiologist Dr. Joël Doré, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. Hervé is also a board member for the French biotech industry association, France Biotech and an active contributor to Allliance Promotion Microbiote, an organization recently founded to support the microbiome sector development in France.

Engineer, MBA,

Jean Volatier

Independent Director

Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l'Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.

CFO

Muriel Prudent

Non-Executive Director

Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan

Dr. Claude Bertrand

Independent Director

Claude joined MaaT Pharma as an independent board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.

PharmD, PhD

Isabelle de Crémoux

Non-Executive Director

Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicle to support the microbiome revolution. Prior to joining Seventure Partners, she worked at Arthur Andersen/ EY, Pfizer and Laboratoires Fournier.

Engineering degree from Ecole Centrale Paris

Nadia Kamal

Independent Director

Nadia Kamal, PhD, Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle, has been appointed in June 2023 as independent director and Chair of the ESG committee. Nadia brings a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation.

Doctorate in immuno-analysis and innovation in clinical biology - Sanofi Diagnostics Pasteur / CNRS
Master's degree in Business Administration from IAE Poitiers
Artificial Intelligence in Health University Diploma at Université Paris Cité

Events & Presentations

2024

December 17th, 2024- KOL discussion on unmet needs in acute Graft-versus-Host Disease and the latest data on MaaT013 from the Early Access Program presented at ASH 2024.

Access the replay here
Dowload the presentation here

December 2024 – Corporate Presentation

November, 21st 2024 – 2024 SFGM-TC Annual Congress – Pooled fecal allogenic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease: results from the early access program in Europe – by Florent Malard, MD, PhD – Professor of Hematology at Sorbonne University, INSERM and Saint-Antoine Hospital in Paris, France

October, 25th 2024 – 2024 SEHH Congress – Allogeneic fecal microbiotherapy as a treatment for refractory Graft-versus-Hostacute gastrointestinal disease: results of the EAP in Europe – by Dr. Jaime Sanz Caballer – Hematologist and coordinator of the Bone Marrow Transplant Unit, University Hospital La Fe in Valencia, Spain

April, 17th 2024 – 2024 EBMT Annual Congress – Presentation of Early Access Program in 140 patients with acute GvHD treated with MaaT013 by Florent Malard, MD, PhD – Professor of Hematology at Sorbonne University, INSERM and Saint-Antoine Hospital in Paris, France